Aclaris Therapeutics, Inc.
ACRS
$6.18
$0.162.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.38% | -31.42% | 79.50% | -92.64% | -40.44% |
| Total Depreciation and Amortization | -6.14% | -20.31% | -28.67% | -38.55% | -52.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.87% | -16.61% | -96.24% | -22.19% | 47.05% |
| Change in Net Operating Assets | -287.22% | 16.02% | 425.55% | -97.61% | 116.21% |
| Cash from Operations | -98.61% | -39.00% | -46.91% | -149.69% | 18.90% |
| Capital Expenditure | -176.19% | 69.77% | -- | -- | -250.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.65% | -261.36% | 111.71% | 395.64% | 836.63% |
| Cash from Investing | 103.35% | -261.79% | 111.69% | 394.81% | 848.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -155.56% | 9.09% | 51.35% | 100.00% | 18.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 53.37% | -- | -- |
| Cash from Financing | 1,111.11% | 21,111.27% | -103.40% | -13,936.36% | 18.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.58% | 50.34% | 77.05% | -100.59% | 61.91% |